Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 4/20 | 0.48 |
| ▸ | ACACA | Q13085 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946595 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL3946631 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL3261678 | 0.95 | ALDH1A1 (0.59) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL3261676 | 0.95 | ALDH1A1 (0.59) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL6642475 | 0.93 | KMT2A (0.52) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL6642481 | 0.93 | KMT2A (0.52) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL13666981 | 0.92 | SYK (0.57) | KMT2ADRD2SYKACACBACACA | |
| SCHEMBL13668666 | 0.92 | SYK (0.57) | KMT2ADRD2SYKACACBACACA | |
| SCHEMBL30442637 | 0.90 | ALDH1A1 (0.58) | ALDH1A1GAATSHRKMT2AL3MBTL1 | |
| SCHEMBL3940932 | 0.90 | ALDH1A1 (0.55) | ALDH1A1GAATSHRKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| EP-0846682-B9 | PENICILLAMINAMIDE DERIVATIVES | MITSUBISHI CHEM CORP (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-0846682-B1 | PENICILLAMINAMIDE DERIVATIVES | MITSUBISHI CHEM CORP (JP) | 2002-10-16 | — | — | EP | disclosed |
| EP-0669317-B1 | Prolineamide derivatives | MITSUBISHI CHEM CORP (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6239150-B1 | POTENT INHIBITORY ACTIVITY AGAINST THROMBIN, AND ARE USEFUL AS ANTICOAGULANTS. | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0846682-A1 | PENICILLAMINAMIDE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0669317-A1 | Prolineamide derivatives | Mitsubishi Chemical Corporation (JP) | 1995-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | ALDH1A1 2250/4885GAA 3010/4885TSHR 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.